Due to such a low incidence of this disease, screening the whole population is neither practical nor appropriate. Current diagnostic markers are very expensive per cancer and are challenged by cost and morbidity associated with invasive testing. Read more . . .
The prognosis of several cancers, including pancreatic tumors, has hardly improved in the last decades, contrasting with a general dramatic increase in survival for most cancers. We felt that a new approach was required.